In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.
News|Podcasts|September 10, 2026
ACT Brief: Explainable AI for Patient Subgroups, Participant Understanding and Engagement, and FDA Leadership Stabilization
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine why black-box AI fails in clinical trials, how participant understanding drives engagement more than gamification, and FDA permanent leadership appointments prioritizing regulatory predictability.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In the
latest Beyond Compliance episode , Joseph Geraci, PhD, co-founder and chief scientific and technical officer at NetraMark, explained why black-box AI models are poorly suited to clinical trial data where regulators and clinicians need to understand how conclusions were reached. Explainable AI capable of recognizing when it lacks sufficient information surfaces clinically meaningful patient subgroups characterized by variables clinicians can recognize and act on, allowing insights from earlier phases to inform later trials. - In a
new contributed article , Aubrey Verna of YPrime examined how participant engagement depends far more on clarity and understanding than on gamification or incentives. Survey data showed 46% of participants identified better understanding of trial importance as the single most impactful engagement factor, far exceeding recognition (39%) and reminders (37%), suggesting engagement must be embedded into trial workflows as a core design element. - The
FDA announced four permanent senior leadership appointments , confirming Michael Davis, MD, PhD, as director of CDER and Karim Mikhail, BPharm, MSc, as director of CBER, while also creating the agency's first-ever Deputy Commissioner for Technology and AI role. Placing AI governance at the deputy commissioner level signals the administration intends AI oversight to be a cross-agency priority, while the center appointments address structural uncertainty that has constrained biotech deal flow and IPO activity throughout 2026.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how China’s trial startup timelines compare with those in the US and Europe, whether AI-drafted clinical study reports speed drug development, and how Bimzelx compared with Skyrizi in psoriatic arthritis.
In today’s ACT Brief, we examine why APAC inspection findings mirror those in the US and Europe, how key risk indicators should be read together, and how FDA granted accelerated approval to a subcutaneous antibody therapy for recurrent head and neck cancer.
In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.
In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
Trending on Applied Clinical Trials Online
1
The Role of Clinical Research Professionals: From Early Discovery to Phase III Success
2
Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices
3
What Smaller Biotechs Need to Get Right in Their First APAC Phase III Trial
4
AI Can Draft the CSR Faster, But Does That Make Drug Development Faster?
5